Search research articles
Contact Us
Filters
Showing results (71-80 of 351) with videos related to
Page
of 36
Sort By:
The Annals of Pharmacotherapy
|
June 28, 2002
Possible gatifloxacin-induced fulminant hepatic failure
Craig I Coleman, Jeffrey V Spencer, Jenny O Chung, et al.
BMC Family Practice
|
February 7, 2012
Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis
Victoria L Baczek, Wendy T Chen, Jeffrey Kluger, et al.
Plos One
|
January 29, 2013
Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis
Craig I Coleman, Matthew F Sidovar, Matthew S Roberts, et al.
Joint Commission Journal on Quality and Patient Safety
|
October 8, 2019
AHRQ Series on Improving Translation of Evidence: Linking Evidence Reports and Performance Measures to Help Learning Health Systems Use New Information for Improvement
C Michael White, Craig I Coleman, Kimberly Jackman, et al.
Journal of Atrial Fibrillation
|
August 7, 2019
Outcomes of Hemorrhagic Stroke Patients with Atrial Fibrillation or Flutter
Sadaf Farasat, Asa Tsoi, Kyulim Lee, et al.
Pharmacotherapy
|
May 8, 2013
Use of preoperative CHA2 DS2 -VASc score to predict the risk of atrial fibrillation after cardiothoracic surgery: a nested case-control study from the Atrial Fibrillation Suppression Trials (AFIST) I, II, and III
William L Baker, Craig I Coleman, C Michael White, et al.
BMJ Open
|
June 25, 2013
Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients
Matthew F Sidovar, Brendan L Limone, Soyon Lee, et al.
Plos One
|
April 30, 2013
Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models
Brendan L Limone, William L Baker, Jeffrey Kluger, et al.
International Journal of Cardiology
|
September 30, 2018
Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life
Elaine Nguyen, Craig I Coleman, Christine G Kohn, et al.
BMJ Open
|
June 22, 2014
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
Elizabeth S Mearns, Jessica Hawthorne, Ju-Sung Song, et al.
Page
of 36
Search research articles
Search
Showing results (71-80 of 351) with videos related to
Sort By:
Page
of 36
The Annals of Pharmacotherapy
|
June 28, 2002
Possible gatifloxacin-induced fulminant hepatic failure
Craig I Coleman, Jeffrey V Spencer, Jenny O Chung, et al.
BMC Family Practice
|
February 7, 2012
Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis
Victoria L Baczek, Wendy T Chen, Jeffrey Kluger, et al.
Plos One
|
January 29, 2013
Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis
Craig I Coleman, Matthew F Sidovar, Matthew S Roberts, et al.
Joint Commission Journal on Quality and Patient Safety
|
October 8, 2019
AHRQ Series on Improving Translation of Evidence: Linking Evidence Reports and Performance Measures to Help Learning Health Systems Use New Information for Improvement
C Michael White, Craig I Coleman, Kimberly Jackman, et al.
Journal of Atrial Fibrillation
|
August 7, 2019
Outcomes of Hemorrhagic Stroke Patients with Atrial Fibrillation or Flutter
Sadaf Farasat, Asa Tsoi, Kyulim Lee, et al.
Pharmacotherapy
|
May 8, 2013
Use of preoperative CHA2 DS2 -VASc score to predict the risk of atrial fibrillation after cardiothoracic surgery: a nested case-control study from the Atrial Fibrillation Suppression Trials (AFIST) I, II, and III
William L Baker, Craig I Coleman, C Michael White, et al.
BMJ Open
|
June 25, 2013
Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients
Matthew F Sidovar, Brendan L Limone, Soyon Lee, et al.
Plos One
|
April 30, 2013
Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models
Brendan L Limone, William L Baker, Jeffrey Kluger, et al.
International Journal of Cardiology
|
September 30, 2018
Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life
Elaine Nguyen, Craig I Coleman, Christine G Kohn, et al.
BMJ Open
|
June 22, 2014
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
Elizabeth S Mearns, Jessica Hawthorne, Ju-Sung Song, et al.
Page
of 36